v3.26.1
Note 11 - Segments - Schedule of Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenues $ 0 $ 1,757,724 $ 0 $ 3,675,215
Research and Development Expense 4,321,772 5,108,625 9,457,191 9,946,423
Stock-based compensation 362,275 497,015 711,471 858,182
Total general and administrative expenses 2,356,779 3,265,374 5,331,884 5,647,951
Other income 106,895 357,871 253,261 766,721
Interest income 104,897 368,127 252,284 777,112
Net loss (6,571,656) (6,258,404) (14,535,814) (11,152,438)
Operating Segments [Member] | Single Reportable Segments [Member]        
Revenues 0 1,757,724 0 3,675,215
Research and Development Expense 4,321,772 5,108,625 9,457,191 9,946,423
Personnel costs, excluding stock-based compensation 1,130,104 1,724,775 2,446,534 2,835,869
Stock-based compensation 225,100 375,856 447,586 613,321
Professional fees 659,065 804,391 1,761,866 1,533,961
Insurance, taxes and similar fees 220,840 248,715 435,604 468,301
Other general and administrative expenses, including IT, facilities, supplies and similar costs*** 121,670 111,637 240,294 196,499
Total general and administrative expenses 2,356,779 3,265,374 5,331,884 5,647,951
Other income 1,998 (10,256) 977 (10,391)
Interest income 104,897 368,127 252,284 777,112
Net loss (6,571,656) (6,258,404) (14,535,814) (11,152,438)
Operating Segments [Member] | Single Reportable Segments [Member] | Dementia with Lewy bodies [Member]        
Research and Development Expense 422,614 1,815,817 1,169,359 3,973,648
Operating Segments [Member] | Single Reportable Segments [Member] | Frontotemporal Disorders [Member]        
Research and Development Expense 495,888 411,029 963,851 557,302
Operating Segments [Member] | Single Reportable Segments [Member] | Recovery After Stroke [Member]        
Research and Development Expense 591,586 303,161 900,538 555,703
Operating Segments [Member] | Single Reportable Segments [Member] | Other Clinical and Nonclinical [Member]        
Research and Development Expense [1] 437,749 532,532 1,469,667 1,207,923
Operating Segments [Member] | Single Reportable Segments [Member] | Personnel Costs [Member]        
Research and Development Expense 872,925 814,878 1,851,838 1,588,602
Operating Segments [Member] | Single Reportable Segments [Member] | Stock Based Compensation [Member]        
Research and Development Expense 137,175 121,159 263,885 244,861
Operating Segments [Member] | Single Reportable Segments [Member] | Other Research and Development Costs [Member]        
Research and Development Expense [2] $ 1,363,835 $ 1,110,049 $ 2,838,053 $ 1,818,384
[1] Includes early-stage clinical studies that are not indication-specific and related costs.
[2] Includes, among other things, CMC-related costs, shipping, packaging and storage costs, certain consulting costs, and other miscellaneous research development expenses.